Last reviewed · How we verify
NCT03723824
Grazoprevir/Elbasvir for Genotype 1b Chronic Hepatitis C After Liver or Kidney Transplantation
Phase 4 trial testing grazoprevir 100 mg/ elbasvir 50 mg, Zepatier® in Chronic Hepatitis c in 14 participants. Terminated before completion.
30 November 2020
Quick facts
| Lead sponsor | Taichung Veterans General Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 14 |
| Start date | 14 February 2019 |
| Primary completion | 30 November 2020 |
| Estimated completion | 13 March 2021 |
| Sites | 2 locations across Taiwan |
Drugs / interventions tested
- grazoprevir 100 mg/ elbasvir 50 mg, Zepatier® — full drug profile →
Conditions studied
- Chronic Hepatitis c — all drugs for Chronic Hepatitis c →
- Liver Transplant Infection — all drugs for Liver Transplant Infection →
- Kidney Transplant Infection — all drugs for Kidney Transplant Infection →
Sponsor
Taichung Veterans General Hospital
Who can join
20 and older, any sex, with Chronic Hepatitis c or Liver Transplant Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Grazoprevir/elbasvir combination therapy is highly effective in the treatment of genotype 1b chronic hepatitis C, and the drug-drug interaction with central immunosuppressant, such as tacrolimus, should be manageable. The aim of this study is to assess the efficacy and tolerability of grazoprevir/elbasvir combination therapy in treating genotype 1b chronic hepatitis C after liver or kidney transplantation.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Grazoprevir/Elbasvir Treatment in Liver or Kidney Transplant Recipients with Genotype 1b Hepatitis C Virus Infection.
Lai PC, Chen CH, Jeng LB, Yu TM, et al · · 2022 · cited 3× · PMID 34902265 · DOI 10.1128/aac.02003-21
Verify or expand the search:
- PubMed search for NCT03723824
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Taichung Veterans General Hospital trials
Trials by the same sponsor.
- NCT06858436 — SGLT2 Inhibitor Utilization Re-perfusion Therapy · Phase 4 · not yet recruiting
- NCT07453953 — A Comparison of Clinical Efficacy of Mytocel MSK With AMT and PRP Injections in Patients With Knee Osteoarthritis · EARLY_PHASE1 · not yet recruiting
- NCT07487636 — 4DryField PH and Head and Neck Operations. · NA · enrolling by invitation
- NCT07284017 — The Impact of Neuronavigation in rTMS for Hemiplegic Stroke Patients. · NA · not yet recruiting
- NCT07363876 — The Efficacy of Ultrasonication in Combination With Corticosteroid Intraarticular Injection for Arthritis · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03723824 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Taichung Veterans General Hospital
- Last refreshed: 16 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03723824.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing